PTC Therapeutics, Inc. (PTCT) Tuesday announced positive data from two different long-term extension studies of vatiquinone in Friedreich ataxia (FA). The primary endpoints of the studies were met. Following the news, the company's shares were trading more than 5 percent up in pre-market.
Friedreich ataxia (FA) is a rare, genetic disorder that causes progressive damage to the nervous system.
Results from the MOVE-FA long-term extension study showed that 144 weeks of vatiquinone treatment resulted in a 3.7-point benefit on the modified Friedreich Ataxia Rating Scale (mFARS). mFARS is a series of physical examination assessments to measure disease progression in patients with FA. PTC said this treatment difference on the primary endpoint represents a 50 percent slowing in disease progression over 3 years.
Additionally, PTC analyzed long-term open-label data from an earlier study of vatiquinone in adults with FA. Following 24-months of treatment with vatiquinone, subjects had a 4.8-point benefit on the mFARS.
The company plans to submit NDA for vatiquinone in December this year.
PTC shares had closed at $34.99, down 0.31 percent on Monday. It has traded in the range of $17.53 - $40.69 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.